This proposal is a Phase II trial of oral administration of a small peptide (DNAj peptide) which bears homology to the class II molecules (shared epitope) in Rheumatoid Arthritis. Work will be conducted at UCSD, John Hopkins University, Mayo Clinic and Instituto Mexicano de Seguro Social, Tijuana. Patients with early RA (5 or less years duration, not exposed to MTX or Enbrel) will be selected based on their immune reactivity with DNAj peptides. Primary outcome is the ACR 20, a standard measure of outcome in RA trials.

Project Start
1999-09-30
Project End
2004-09-29
Budget Start
2000-09-20
Budget End
2001-09-29
Support Year
Fiscal Year
2000
Total Cost
$759,413
Indirect Cost
Name
University of California San Diego
Department
Pediatrics
Type
Schools of Medicine
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Albani, Salvatore; Prakken, Berent (2006) T cell epitope-specific immune therapy for rheumatic diseases. Arthritis Rheum 54:19-25
Giannoni, Francesca; Barnett, Joellen; Bi, Kun et al. (2005) Clustering of T cell ligands on artificial APC membranes influences T cell activation and protein kinase C theta translocation to the T cell plasma membrane. J Immunol 174:3204-11
Prakken, Berent J; Samodal, Rodrigo; Le, Tho D et al. (2004) Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A 101:4228-33
de Kleer, Isme M; Wedderburn, Lucy R; Taams, Leonie S et al. (2004) CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 172:6435-43
Utz, P J; Genovese, M C; Robinson, W H (2004) Unlocking the ""PAD"" lock on rheumatoid arthritis. Ann Rheum Dis 63:330-2
Massa, Margherita; Costouros, Nick; Mazzoli, Federica et al. (2002) Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum 46:3015-25